Resmed (RSMDF) Liabilities from Discontinued Operations (2026)
Resmed's (RSMDF) quarterly Liabilities from Discontinued Operations came in at $41.2 million in Q2 2026.
Powered by 
Analysis
Resmed (RSMDF) Liabilities from Discontinued Operations (2026) Analysis & Trends
Resmed (RSMDF) has reported Liabilities from Discontinued Operations for 1 consecutive years, with $41.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities from Discontinued Operations changed N/A year-over-year to $41.2 million; the trailing twelve-month figure through Jun 2026 stood at $41.2 million (changed N/A YoY), and the FY2026 full-year result was $41.2 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at $41.2 million in Q2 2026 per RSMDF's latest filing.
- Across five years, Liabilities from Discontinued Operations topped out at $41.2 million in Q2 2026 and bottomed at $41.2 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.06 Bn | 178.46 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 124.29 Bn | 119.08 Bn | 1.96 Bn |
| 3 | Medtronic | 118.26 Bn | 109.44 Bn | 6.34 Bn |
| 4 | Stryker | 104.56 Bn | 101.08 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.33 Bn | 65.79 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.62 Bn | 45.37 Bn | 1.35 Bn |
| 7 | Alcon | 33.94 Bn | 32.48 Bn | 1.68 Bn |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn |
| 9 | Steris | 21.14 Bn | 20.65 Bn | 684.20 Mn |
| 10 | Resmed | 3.54 Bn | 2.07 Bn | 861.22 Mn |